Daily Roundup

Tuesday, 20th January 2026
Last updated: 21:00 | Max Version 🚀

HUB.ASX ARB.ASX NST.ASX TLX.ASX QOR.ASX

HUB24 Delivers Record Q2 and Half-Year Results

HUB24 Ltd has reported a stellar performance in the second quarter and first half of FY2026, with the company's platform delivering record net inflows and growing its total funds under administration (FUA) to $152.3 billion.

The company recorded $5.6 billion in net inflows for Q2, a new quarterly record, and $10.7 billion in net inflows for the first half - up 13% on the prior corresponding period. This drove total FUA to $152.3 billion as of 31 December 2025, a 26% increase year-over-year.

HUB24 continued to gain market share, ranking first for quarterly and annual net inflows for the eighth consecutive quarter. The company also signed 34 new distribution agreements during the quarter, bringing the total number of advisers using the platform to 5,277 - an 8% increase.

Alongside the strong growth, HUB24 has been investing to deliver innovative solutions, including the development of a lifetime retirement product with TAL and a new ecosystem concept called myhub to address productivity challenges for advice practices.

Looking ahead, HUB24 remains committed to enhancing its market-leading proposition and driving productivity and efficiency for advisers and their clients through continued platform enhancements and innovative offerings.

ARB Corporation Navigates Headwinds in First Half

ARB Corporation reported a mixed performance in the first half of FY2026, with total sales revenue declining 1.0% to $358.0 million and underlying profit before tax dropping 16.3% to $58.0 million.

The company cited a weaker Australian dollar against the Thai baht and lower factory overhead recoveries as the key factors behind the profit decline. However, ARB's export sales grew 8.8% during the period, with the crucial US market up 26.1%.

While sales to the Australian Aftermarket channel declined 1.7%, the company noted ongoing fitting capacity constraints in the country. ARB's OEM channel sales in Australia also fell 38.2% due to the timing of contracts and model releases.

Looking at the balance sheet, ARB held $59.4 million in cash with no debt at the end of December 2025, after paying the FY2025 final dividend and a special dividend.

Northern Star Revises Cost Guidance Amid Lower Production

Northern Star Resources has updated its FY2026 cost guidance, revising the All-In Sustaining Cost (AISC) range to A$2,600-2,800 per ounce, up from the previous A$2,300-2,700 per ounce.

The revision is driven by lower gold sales and higher royalties resulting from elevated gold prices. Northern Star had previously reduced its FY2026 production guidance to 1,600-1,700 thousand ounces, down from 1,700-1,850 thousand ounces.

Despite the cost headwinds, the company's FY2026 sustaining capital guidance of approximately A$750 million remains unchanged, corresponding to around A$450 per ounce (versus the previous A$420 per ounce).

Northern Star will release its December quarter results on 22 January 2026, providing further details on the operational and financial performance.

Telix Achieves FY2025 Guidance with Strong Q4 Growth

Telix Pharmaceuticals Limited has reported a strong finish to FY2025, delivering unaudited Group revenue of approximately US$804 million (A$1.2 billion) - in line with its upgraded guidance.

The company's Q4 2025 unaudited Group revenue reached US$208 million, up 46% year-over-year, driven by growth in the Precision Medicine business. This included the successful US launch of Gozellix, which received reimbursement from the Centers for Medicare and Medicaid Services.

Telix also made progress on the clinical front, with the first international patients treated in the ProstACT Global Phase 3 study for advanced prostate cancer, and the first US patients enrolled in the SOLACE Phase 1 study for pain from bone metastases.

Additionally, the company announced a strategic collaboration with Varian, a Siemens Healthineers company, to explore the combination of Telix's radiopharmaceuticals with external beam radiation therapy.

Qoria Delivers Record ARR Growth in Q2 FY2026

Qoria Ltd has reported a standout performance in the second quarter and first half of FY2026, with the company adding a record $5.1 million in net Annual Recurring Revenue (ARR) - a 42% increase compared to the prior December quarter.

Qoria's ARR reached $154 million on a consistent currency basis, or $149 million after FX adjustments. The company also saw a 20% increase in cash receipts for the half-year, reaching $79.1 million, and a 46% jump in free cash flow to $8.9 million.

The strong results were driven by exceptional growth in Qoria's K12 business, which delivered record ARR growth of $4.6 million (before churn) and $3.0 million net, with strong performance across all segments, particularly in Australia. The company's Qustodio consumer business also continued to thrive, with an annualized ARR growth rate of 34% in H1 FY2026.

Looking ahead, Qoria has guided for FY2026 revenue of over $145 million, ARR growth of 20%, an EBITDA margin of 20%, and positive free cash flow for the full year. The company remains well-positioned for further growth, with a record weighted K12 pipeline of $14 million, up 29% year-over-year.